commercial normal reference plasma standard human plasma (Siemens AG)
90
Structured Review
Siemens AG
commercial normal reference plasma standard human plasma
Commercial Normal Reference Plasma Standard Human Plasma, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/reference+normal+human+plasma/standard+human+plasma+from+healthy+volunteers/pmc07982284-88-12-18
Average 90 stars, based on 1 article reviews
Commercial Normal Reference Plasma Standard Human Plasma, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/reference+normal+human+plasma/standard+human+plasma+from+healthy+volunteers/pmc07982284-88-12-18
Average 90 stars, based on 1 article reviews
commercial normal reference plasma standard human plasma - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Activity Assay:Article Title: Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Article Snippet: An additional Siemens Innovance ‘VWF activity assay’, or ‘VWF Ac’, representing a direct GPIb binding assay, and previously validated by us and by others as representing a similar assay profile to VWF:RCo [12–15], was also included in this study for comparative evaluation purposes. .. We employed the following controls for this evaluation: (a) For the VWF:Ag, VWF:CB and VWF:RCo reference methods and for VWF Ac, plus all reference method activity/Ag ratios, we utilized several commercial controls: (i) Article Title: Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Article Snippet: U. MARTINOWITZ,* J. BJERRE, B.. BRAND, R. KLAMROTH,§ M. MISGAV,* M. MORFINI,– E. SANTAGOSTINO,** A. TIEDE and D. VIUFF *Institute of Thrombosis and Hemostasis and the National Hemophilia Center, The Chaim Sheba Medical Center, Tel Hashomer, affiliated to Sacker School of Medicine, Tel Aviv University, Israel; Medical and Science, Haemophilia, Novo Nordisk A/S, Søborg, Denmark; University Hospital, Division of Haematology, Zurich, Switzerland; §Vivantes Klinikum im Friedrichshain, Klinik für Innere Medizin – Angiologie und Hämostaseologie, Berlin, Germany; –Agency for Haemophilia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy; **Department of Internal Medicine and Medical Specialties, Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, IRCCS Cà Granda Foundation, Maggiore Hospital Policlinico and University of Milan, Milan, Italy; and Hannover Medical School, Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany Clinical Proteomics:Article Title: Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Article Snippet: An additional Siemens Innovance ‘VWF activity assay’, or ‘VWF Ac’, representing a direct GPIb binding assay, and previously validated by us and by others as representing a similar assay profile to VWF:RCo [12–15], was also included in this study for comparative evaluation purposes. .. We employed the following controls for this evaluation: (a) For the VWF:Ag, VWF:CB and VWF:RCo reference methods and for VWF Ac, plus all reference method activity/Ag ratios, we utilized several commercial controls: (i) Article Title: Von Willebrand factor proteins for treating bleeding disorders Article Snippet: Factor VIII chromogenic SP4 assay was purchased from Diapharma (Chester, OH). .. Article Title: Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Article Snippet: U. MARTINOWITZ,* J. BJERRE, B.. BRAND, R. KLAMROTH,§ M. MISGAV,* M. MORFINI,– E. SANTAGOSTINO,** A. TIEDE and D. VIUFF *Institute of Thrombosis and Hemostasis and the National Hemophilia Center, The Chaim Sheba Medical Center, Tel Hashomer, affiliated to Sacker School of Medicine, Tel Aviv University, Israel; Medical and Science, Haemophilia, Novo Nordisk A/S, Søborg, Denmark; University Hospital, Division of Haematology, Zurich, Switzerland; §Vivantes Klinikum im Friedrichshain, Klinik für Innere Medizin – Angiologie und Hämostaseologie, Berlin, Germany; –Agency for Haemophilia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy; **Department of Internal Medicine and Medical Specialties, Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, IRCCS Cà Granda Foundation, Maggiore Hospital Policlinico and University of Milan, Milan, Italy; and Hannover Medical School, Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany Article Title: Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use Article Snippet: .. To our knowledge, at least one group of researchers have verified commercial Article Title: Abstracts of the XXIV Congress of the International Society on Thrombosis and Haemostasis. June 29-July 4, 2013. Amsterdam, The Netherlands. Article Snippet: Assays: OS assay using the SynthASil (Instrumentation Laboratory) aPTT reagent and CS assay based on the Coamatic kit (Chromogenix). .. All measurements were done against commercial Article Title: Using a Biosensor Based on Surface-Enhanced Raman Scattering to Identify Influenza Viruses in Biological Fluids Article Snippet: The following modified DNA oligonucleotides were used as aptamers: thiol-modified aptamer RHA0385-SH (5'-HS-(CH 2 ) 6 -TTGGGGTTA-TTTTGGGAGGGCGGGGGTT-3') from Sintol (Russia) and aptamer BodipyFL-RHA0385-BDPFL with SERS-active label (5'-BODIPY FL-TTGGGGTTATTTTGGGAGGGCGGGGGTT-3') from Lumiprobe (Russia). .. Article Title: Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Article Snippet: Contents lists available at ScienceDirect Clinica Chimica Acta j ourna l homepage: www.e lsev ie r .com/ locate /c l inch im Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome R. Mondejar a, C. González-Rodríguez a,⁎, F.J. Toyos-Sáenz de Miera a, E. Melguizo-Madrid a, N. Zohoury b, M. Mahler b, I. Romero Losquiño a, F. Fabiani a a Virgen Macarena University Hospital, Seville, Spain b INOVA Diagnostics, Inc., San Diego, CA, USA ⁎ Corresponding author at: Clinic Biochemistry Servic Hospital.. Avda.. Dr. Fedriani s/n, 41072 Seville, Spain. Article Title: Predictive immunogenicity of Refacto AF. Article Snippet: S. DELIGNAT,*†‡ Y. REPESS E,§ L. GILARDIN,*†‡ J . D. DIMITROV,*†‡** Y.C.. LONE,¶ S. V. KAVERI*†‡** and S. LACROIX-DESMAZES*†‡** *Institut National de la Sant e et de la Recherche M edicale (INSERM), Unit e Mixte de Recherche en Sant e (UMR S), Paris, France; †Universit e Pierre et Marie Curie–Paris 6, UMR, Paris, France; ‡Universit e Paris Descartes, UMR S Centre de Recherche des Cordeliers, Paris, France; §Haemophilia Centre, University Hospital of Caen, Caen, France; ¶INSERM, Hôpital Paul Brousse Bâtiment INSERM Lavoisier, Villejuif, France; and **International Associated Laboratory IMPACT (INSERM, France–Indian Council of Medical Research, India), National Institute of Immunohaematology, Mumbai, India Control:Article Title: Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Article Snippet: An additional Siemens Innovance ‘VWF activity assay’, or ‘VWF Ac’, representing a direct GPIb binding assay, and previously validated by us and by others as representing a similar assay profile to VWF:RCo [12–15], was also included in this study for comparative evaluation purposes. .. We employed the following controls for this evaluation: (a) For the VWF:Ag, VWF:CB and VWF:RCo reference methods and for VWF Ac, plus all reference method activity/Ag ratios, we utilized several commercial controls: (i) Article Title: Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use Article Snippet: .. To our knowledge, at least one group of researchers have verified commercial Article Title: Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Article Snippet: Contents lists available at ScienceDirect Clinica Chimica Acta j ourna l homepage: www.e lsev ie r .com/ locate /c l inch im Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome R. Mondejar a, C. González-Rodríguez a,⁎, F.J. Toyos-Sáenz de Miera a, E. Melguizo-Madrid a, N. Zohoury b, M. Mahler b, I. Romero Losquiño a, F. Fabiani a a Virgen Macarena University Hospital, Seville, Spain b INOVA Diagnostics, Inc., San Diego, CA, USA ⁎ Corresponding author at: Clinic Biochemistry Servic Hospital.. Avda.. Dr. Fedriani s/n, 41072 Seville, Spain. Coagulation:Article Title: Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Article Snippet: Contents lists available at ScienceDirect Clinica Chimica Acta j ourna l homepage: www.e lsev ie r .com/ locate /c l inch im Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome R. Mondejar a, C. González-Rodríguez a,⁎, F.J. Toyos-Sáenz de Miera a, E. Melguizo-Madrid a, N. Zohoury b, M. Mahler b, I. Romero Losquiño a, F. Fabiani a a Virgen Macarena University Hospital, Seville, Spain b INOVA Diagnostics, Inc., San Diego, CA, USA ⁎ Corresponding author at: Clinic Biochemistry Servic Hospital.. Avda.. Dr. Fedriani s/n, 41072 Seville, Spain. Incubation:Article Title: Predictive immunogenicity of Refacto AF. Article Snippet: S. DELIGNAT,*†‡ Y. REPESS E,§ L. GILARDIN,*†‡ J . D. DIMITROV,*†‡** Y.C.. LONE,¶ S. V. KAVERI*†‡** and S. LACROIX-DESMAZES*†‡** *Institut National de la Sant e et de la Recherche M edicale (INSERM), Unit e Mixte de Recherche en Sant e (UMR S), Paris, France; †Universit e Pierre et Marie Curie–Paris 6, UMR, Paris, France; ‡Universit e Paris Descartes, UMR S Centre de Recherche des Cordeliers, Paris, France; §Haemophilia Centre, University Hospital of Caen, Caen, France; ¶INSERM, Hôpital Paul Brousse Bâtiment INSERM Lavoisier, Villejuif, France; and **International Associated Laboratory IMPACT (INSERM, France–Indian Council of Medical Research, India), National Institute of Immunohaematology, Mumbai, India |